Pfizer (PFE) has a long road ahead as it's first quarter earnings report showed a fall in sales by 9% and even worse are the other disappointing trends in Pfizer's biggest products. Sales of Prevnar, Lipitor, and Viagra have all dipped this last year as similar but less expensive generic drugs compete with them. While Pfizer did profit in the last quarter, it was less than the analysts expected and the share price will likely suffer from that.
Tuesday, April 30, 2013
Pfizer (PFE): Too many Viagra jokes about limping sales
Pfizer (PFE) has a long road ahead as it's first quarter earnings report showed a fall in sales by 9% and even worse are the other disappointing trends in Pfizer's biggest products. Sales of Prevnar, Lipitor, and Viagra have all dipped this last year as similar but less expensive generic drugs compete with them. While Pfizer did profit in the last quarter, it was less than the analysts expected and the share price will likely suffer from that.
